Background: Published studies suggesting a relationship between vitamin D and some common cancers sparked interest in the association of vitamin D with head and neck cancers. Prolonged darker months in Finland are associated with lower levels of ultraviolet B radiation, raising concerns about low vitamin D levels.
Introduction
Head and neck cancer is a general term that includes epithelial malignancies that arise in the nasal cavity, paranasal sinuses, oral cavity, pharynx, or larynx (1) . Head and neck cancer is the sixth most common cancer, with about 650,000 new cancer cases and 350,000 worldwide each year (1) . Widely recognized risk factors include tobacco and alcohol, which account for an estimated 75% of head and neck cancers in industrialized regions. Human papilloma virus (HPV) infection has also been implicated in an increasing fraction of cancers of the head and neck (2, 3) .
Ecologic studies have suggested that populations with more solar UV radiation exposure, the primary source of vitamin D for most people, have lower rates of some cancers (4) . Observational studies preferentially use individual exposure measures and serum 25(OH)D concentration seems to be a reasonably stable assessment of vitamin D status (5) . Many studies have used this marker to test the association between vitamin D and cancers of the breast, colon, prostate, and some rarer cancers (4, (6) (7) (8) (9) (10) (11) (12) . Some studies show an association between higher concentrations of serum vitamin D and a reduced risk of prostate, colon, and breast cancer incidence and/or mortality (4, 6) . Higher 25(OH)D, however, has been associated with increased risk of pancreatic (12, 13) and upper gastrointestinal tract cancers (7, 14) .
The relationship between vitamin D and head and neck cancers has only minimally been explored. At present, there is no published literature on serum vitamin D and incidence of head and neck cancers in humans, and a recent study exploring the relationship between dietary vitamin D, serum 25(OH)D, and head and neck cancer prognosis found no association (15) . One prospective study in men using predicted 25(OH)D level based on participant characteristics showed an association between predicted plasma 25(OH)D level and risk of oral and pharyngeal cancers combined (relative risk: 0.30; 95% CI: 0.11-0.81) but did not report on the association with larynx cancer (16) .
The current prospective study examines the association between serum 25(OH)D concentration and the risk of developing cancer of the oral cavity, pharynx, and larynx (a subset of all head and neck cancers) in a nested casecontrol study within the Alpha-Tocopherol Beta-Carotene Cancer Prevention (ATBC) Study.
Materials and Methods

Study population
Cases and controls were selected from the ATBC Study cohort, a randomized, double-blind, placebo-controlled primary cancer prevention trial. Study design, methods, and rationale have been published elsewhere (17) . Participants included 29,133 males between the ages of 50 to 69 years from southwestern Finland who smoked 5 or more cigarettes daily. Enrollment occurred between 1985 and 1988 and participants completed baseline questionnaires on general characteristics, medical history, smoking, dietary, and physical activity history. At baseline, staff collected anthropometric measurements and calculated body mass index (BMI) from height and weight. Serum alpha-tocopherol, beta-carotene, and retinol were assessed using high performance liquid chromatography assay (17) . The randomization scheme was based on a 2 Â 2 factorial design, assigning participants to alpha-tocopherol (50 mg/d), beta-carotene (20 mg/d), both alphatocopherol and beta-carotene, or a placebo. Follow-up for cancer incidence and cause-specific mortality continues through the Finnish Cancer Registry with nearly 100% case ascertainment (18) . All participants provided written informed consent and the Institutional Review Boards of both the National Public Health Institute in Finland and the U.S. National Cancer Institute approved the study.
Case identification and control selection
There were 348 incident cases of head and neck cancer as defined by the International Classification of Diseases 9 codes: 140-145 (oral cavity), 146-149 (pharynx), and 161 (larynx) diagnosed between September 1985 and April 2005. We excluded non-squamous cell carcinomas and metastatic tumors of nonspecific origin (n ¼ 8). The final number of cases (n ¼ 340) included 134 oral cavity, 48 pharynx, and 158 larynx cancer cases. Controls were alive and free of cancer at the time of case diagnosis and were matched to cases (1:1) on age at randomization (AE1 year) and date of baseline serum collection (AE30 days).
Serum 25-hydroxyvitamin D measurements and exposure metrics
At the prerandomization visit, fasting serum samples were collected and stored at À70
C. There were no participant visits or blood collection during July, and relatively few in June and August. The samples were measured for 25 (OH)D with the DiaSorin Liaison 25(OH)D TOTAL Assay Platform using a direct, competitive chemiluminescence immunoassay at Heartland Assays, Inc. in early 2008 (19, 20) . Previous research shows that 25(OH)D concentrations are correlated in samples assayed up to 14 years apart (5, (21) (22) (23) (24) . Methods used for this sample have been described in detail elsewhere (20) . In short, matched case-control sets were placed in the same batch, with 4 or 6 quality controls samples from both the ATBC pool and the National Institute of Standards and Technology (NIST) standard reference material no. 972. For the NIST sample, the median interbatch coefficient of variation (CV) for cohort quality control samples was 13.2% (range: 4.8%-17.0%), and the intrabatch CV was 9.9% (range: 3.8%-16.4%). For the ATBC pool, interbatch and intrabatch CVs for duplicate aliquots were 12.3% and 10.5%, respectively.
Serum concentrations for the primary analyses used 5 a priori defined 25(OH)D categories based on cutoff points thought to have clinical relevance: <25, 25-<37.5, 37.5-<50, 50-<75 (reference), and >75 nmol/L. Previously published studies used these cutoff points (20) , and the reference level of 50 to <75 nmol/L includes the mean for subjects in the U.S. National Health and Nutrition Examination Survey (25) . We also constructed 2 other metrics for exposure that account for seasonal differences in mean serum 25(OH)D because a simulation study indicated that using season-specific cutoff points reduced the bias associated with different dates of blood draw (26) . First, we created season-specific quartile cutoff points using the distribution of control samples within each season (defined below). Second, we created quartiles of residual-based vitamin D measure which adjusted out the effect of season, using the Local Polynomial Regression Method (SAS Proc LOESS) to regress log-transformed 25(OH)D against calendar week of blood collection (27) . We also stratified our analyses by season of blood draw to create a "season-adjusted" measure, which is defined as "darker months" (November-April) and "sunnier months" (May-October) based on monthly median 25(OH)D concentrations among controls.
Statistical analysis
Descriptive analyses comparing cases and controls used c 2 tests for categorical variables and Wilcoxon rank sum tests for continuous variables. Crude and adjusted conditional logistic regression models were used to estimate the association between serum vitamin D and head and neck cancers. Trend tests used a scored serum vitamin D level of either 1 to 4 or 1 to 5 as appropriate. All reported P values are 2-sided and an a error level was set at less than 0.05. All statistical analysis was carried out using SAS 9.2 (SAS Institute, Inc.).
Serum 25(OH)D had a skewed distribution, which we corrected using log transformation. Variables assessed for confounding included age, pack-years, cigarettes per day, smoking years, alcohol intake, BMI, physical activity (both leisure and occupational), history of hypertension, history of diabetes, dentures, missing teeth, daily calorie intake, fish intake, serum retinol, serum alpha-tocopherol, serum beta-carotene, serum cholesterol, high density lipoprotein (HDL), season of blood draw, marital status, and vacations to sunny areas. Potential confounders associated with cancers of the oral cavity, pharynx, or larynx were added to the univariate model to test whether there was a change of greater than 10% in the 25(OH)D coefficients.
We considered variables that showed a significant relationship with both outcome and exposure at a 0.10 statistical significance level for the final model. Using backward selection, we included all variables and conducted stepwise elimination of variables with the highest P value until all variables included in the model were significant at a 0.05 level. Variables excluded from the model did not change betas by more than 10%. The final models included adjustment for continuous age, packyears, BMI, alcohol intake [categorized as missing, no alcohol, up to 1 drink (reference), 1-3 drinks, or greater than 3 drinks per day], and serum beta-carotene.
The primary analyses treated all head and neck cancers as a single outcome, but we also report models examining cancers of the oral cavity, pharynx, and larynx separately. We further explored potential risk modifiers using unconditional logistic regression, based on median split categories for age, BMI, pack-years, alcohol drinks per day, serum alpha-tocopherol, serum beta-carotene, and alpha-tocopherol and beta-carotene intervention groups. To conserve power, we maintained serum 25(OH)D concentration as a continuous measure by scaling the change in risk associated with a 15 nmol/L increase in 25(OH)D serum concentration. Because of a large mode in the number of cigarettes consumed daily, in Figure 1 , we categorized tobacco as less than 20 cigarettes per day, 20 cigarettes per day, and greater than 20 cigarettes per day. To examine whether there was evidence of reverse causation in cases with serum collected most proximate to the time of blood collection, we also modeled the data excluding cases diagnosed during the first two years of follow-up and also models stratified on median diagnosis date (April 15, 1996). Using the predefined clinical cutoff points, serum 25 (OH)D was not associated with risk of head and neck cancer either overall, by subsite, or by season (Table 2) . We tested the alternative exposure metrics of seasonspecific and season-adjusted quartiles (Table 3) . Neither construct showed a significant association between serum 25(OH)D and risk of head and neck cancers.
Results
Exclusion of cases diagnosed within two years of blood collection did not alter the relationship between vitamin D and cancer, nor did an analysis stratified by median diagnosis date (data not shown). Models stratified by the median for potentially interacting variables age, BMI, smoking, alcohol intake, serum beta-carotene, trial supplementation group, or season of blood draw also did not show significant differences for the association between 25(OH)D and head and neck cancers (Fig. 1) .
Discussion
This study found no relationship between serum 25 (OH)D and head and neck cancer among white, male smokers. Testing the association with cancer risk using concentrations of vitamin D based on a priori, seasonspecific, or season-adjusted cutoff points each suggested a null relationship. The null association remained in strata of many potential risk modifiers. This study is a first attempt to inform reports such as the World Cancer Research Fund's Expert Report on Diet or the International Agency for Research on Cancer's report on Vitamin D and Cancer, as previous data were not available for the association between serum vitamin D and incidence of head and neck cancer. Animal models (28) , ecologic studies (29, 30) , and an observational epidemiologic study based on predicted vitamin D exposure (16) suggest reduced risk of head and neck cancers for higher vitamin D exposures. Although this study conflicts with the previously published prediction model suggesting a 70% (95% CI: 0.17-0.80) reduction in risk for oral and pharyngeal cancers, the previous publication was based on predicted, and not measured, 25(OH)D levels (16) . The study was also conducted in a U.S. population, where average serum 25(OH)D is higher, and although most head and neck cancer cases are smokers, the study included a mixture of smokers and nonsmokers.
A recent animal study found that treatment with vitamin D 3 delayed carcinogenesis in the hamster buccal pouch model, but exposure to the carcinogen was initiated at the time of vitamin D dosing and the relationship has not been extended to humans (28) . An early phase human trial examined whether treatment with 25-hydroxyvitamin D 3 reduces immune inhibitory CD34 þ progenitor cell levels and improves immune parameters, as head and neck squamous cell carcinoma patients often present with great immune defects. The study found no evidence of clinical benefit but did report a positive association between vitamin D treatment and reduced numbers of immunosuppressive cells (31) .
The strengths of this study are multiple. It is the first to date study that examines head and neck cancer incidence in relation to serum 25(OH)D. The prospectively collected data minimize recall bias for behavioral risk factors such as alcohol and tobacco consumption and also minimize reverse causality in the serum measure. Furthermore, In this study, we observed no overall or site-specific associations between serum 25(OH)D concentrations and risk of head and neck cancer. Future studies including women, non-white populations and non-smokers may further shed light on the relationship between head and neck cancer incidence and vitamin D.
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